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In previous publications (1, 2) we have described some of the characteristics of transcortin, a plasma protein (or proteins) with high affinity for cortisol and corticosterone. In addition, we have shown that plasmiia transcortin levels are elevated during pregnancy and following administration of estrogens (1) (2) (3) . A different interpretation of the findings in these two states has been given by Daughaday and AMariz (4, 5) . Transcortin levels were substantially lower in the plasma of newborn infants (umnbilical vein 1lood)1 than those found in adult subjects or in older children (2) . The purpose of this paper is to present results of further studies on transcortin levels in human sub- jects under variotus condlitions and the effects of admiiniistered steroi(ls on these levels.
MI ETHODS AND MATERIALS
The binding of C'4-cortisol by plasma transcortin and the transcortiin capacity were determined by methods previously described (1, 2) . The terms "transcortin binding of C'4-cortisol" and "transcortin capacity" have been defiine(d in a previous publication (2) . At this point it may be appropriate to reiterate some important aspects of the methodologies and terms used. Most of the binding experiments wvere performed by dialyzing 10 ml of diluted plasma (1: 5 with physiological saline) against 30 ml of saline containiing approximately 0.3 mg of C14-cortisol. The binding was (letermined with and without the addition of 1 ,ug of cortisol to the saline in order to measure the decrease in the binding caused by the addition of the carrier cortisol. In previously published work (1) we deimioinstrated that un(ler the con(ditions of our assay tlle bindinig of cortisol by plasma was essentially due to transcortini and not to other plasma proteins. Hence, the term "transcortiin bindiing of C'4-cortisol" will refer to the percentage of C'4-cortisol bound by 10 ml of diluted plasma and the term "transcortin capacity" will be used to in(licate the decrease in bindinig caused by the addition of 1 ,ug of cortisol in the dialysis conditions outlined above. It should be pointed out that the "binding capacity" will be inversely related to the decrease in the biniding caused by the addition of 1 ug of cortisol to normal plasma, i.e., the less the decrease in the binding the higher the binding capacity, and vice versa. The measurement of the binding capacity by the method outlined above seems to offer, at the moment, the most practical and sensitive index of traniscortin capacity. It should be realized, however, that this measures the difference between two variables, the level of transcortin and the level of 17-hydroxycorticosteroids (17-OHCS).
Lymph was collected from the thoracic ducts of patients with advanced cancer in ice-chilled bottles and diluted 1: 5 with saline for the determination of the binding of C'4-cortisol. The lymph used constituted an aliquot of a 24 hour specimen, whereas the binding of plasma was determined on blood obtained between 8 and 11 a.m.
The 17-OHCS levels were determined by the method of Peterson, Karrer an(l Guerra (6) . Blood from postoperative patients was obtained in the recovery room, usually 30 to 60 minutes after completion of the operation. The control samples oni the same patients were drawn several days preoperatively. The plasma and lymph samples were frozen whenever shipped or stored. The erythrocytes were separated from the plasma by centrifugation. The plasma and the upper layer of the red blood cells were removed by aspiration. The erythrocytes were then washed three times with three volumes of physiological saline, the cells being spun down after each washing.
The C'4-labeled dihydro-and tetrahydrocortisone acetates were converted to the free alcohols by incubation with acetyl cholinesterase.
In the double equilibrium dialysis the technique of Daughaday, Mariz, Kozak and Biederman was followed (5, 7) . Thus, under these conditions, the different plasmas (from normal subjects, patients receiving estrogens, and pregnant women), and the transcortin therein, were made to compete not only for the added C14-cortisol, but also for the endogenous cortisol present in the plasmas. In addition, the binding exhibited by the same plasmas (diluted and undiluted) was determined by methods described previously (2) .
RESULTS
For a better understanding of the results to be presented, it may be worthwhile to discuss briefly some of the salient features of the binding of transcortin and cortisol. In Figure 1 are shown two representative curves based on data obtained in our laboratory. At low cortisol concentrations the transcortin in normal plasma will bind the steroid almost quantitatively, resulting in the left plateaulike part of the "control" curve. When the concentration of transcortin is increased (e.g., following estrogen administration) the plateau is extended to the right, as in the "test" curve. In addition, when the concentration of cortisol is increased the resultant decrease in the binding (which we call "transcortin capacity") will be smaller in the "test" plasma than in the "control" one. With increasing concentrations of cortisol a sigmoid curve is obtained, ending in a plateau-like right shoulder of the curves. In most of the studies to be reported the determination of transcortin binding was associated with the left half of the curve, with the result that small decreases in binding, upon the addition of 1 ,ug of cortisol in the standard test, indicated an increased transcortin capacity. In a few studies (surgical stress, ACTH and cortisol administration) the determinations were associated with the lower right half of the curve with the result that the binding of C14-cortisol in the standard test was already low and the decrease in binding upon the addition The "test" curve is applicable to plasma obtained from subj ects receiving estrogen therapy and containing an increased transcortin concentration. The ''control" curve applies to plasma of normal subjects. When 0.5 ,g of cortisol is present, the binding by the transcortin in the "control" plasma is only slightly lower than that in the "test" plasma. At a concentration of 5.5 ,ug of cortisol, however, the binding by the cortisol plasma is considerably lower than that of the "test" plasma, indicating a lower transcortin capacity in the former plasma than in the latter. At very high concentrations of cortisol (right side of the curve) the differences in the transcortin binding between the two plasmas are again for another group of 10 normal subjects (2) . The most likely explanation for these differences may be the fact that the bloods in the present study were drawn mostly between 8 and 10 a.m., whereas in the previous study the bloods were obtained in the afternoon. Since the plasma 17-OHCS are known to be higher and to vary more in the afternoon than in the morning, one might expect lower binding of C14-cortisol with more spread in the binding values with such plasmas. in patients who had received stilbestrol for a short cortin capacity, 22 per cent; and plasma 17-period of time, but persisted for at least 10 days to OHCS, 22 ,tg per 100 ml. In two of the 2 weeks in patients on prolonged stilbestrol treat-subjects 17-OHCS and transcortin levels were element. vated within two days, and in all the subjects the The administration of 2.5 mg of Premarin daily levels were increased within a week following for as long as 18 days failed to raise the transcortin the daily administration of 10 nmg of Premarin. The highest transcortin binding of C14-cortisol and failed to change the transcortin and 17-OHCS transcortin capacity were 98 and 12 per cent, re-levels significantly, even when administered for spectively. The highest 17-OHCS level was 46 as long as 76 days. The administration of large ,ug per 100 ml. Elevation of plasma transcortin doses (100 mg i.m. three times weekly) of testosand 17-OHCS levels were seen in all patients re-terone propionate to 15 additional subjects, inceiving stilbestrol or ethinyl estradiol in the dosage cluding 10 postmenopausal women with cancer employed. Three patients with cancer of the of the breast, and 2a-methyl-dihydrotestosterone breast received 16a-estradiol dipropionate (5 mg propionate (100 mg three times weekly) to three three times weekly i.m.) and no changes were seen subjects failed to change the transcortin levels either in the transcortin or 17-OHCS levels. The significantly. In addition, Patient M. W. (Table  administration Transcortin levels postpartum. Transcortin The administration of testosterone propionate (100 levels have been shown to be elevated during pregmg i.m. three times weekly) to three subjects nancy, especially during the last trimester (1). The transcortin binding of CG4-cortisol and ca-cortin capacity, 24 + 3.9 per cent; and plasma pacity were determined in a group of 14 women 1 17-OHCS, 9 + 6.2 jug per 100 ml. hour, 2 days and 5 days postpartum, as well as 6
Comparison of miethods. A comparison of the weeks thereafter (Table II) . The transcortin ca-binding of C14-cortisol ly plasmas from normal pacity in the immediate postpartum samples con-subjects, pregnant women, and subjects treated tinued to be elevated, accomiipanied by very high with estrogens was made by two different tech-17-OHCS levels in some of the patients. By the niques. Daughaday and associates (7, 8) in their fifth day postpartum the values for the transcortin studies failed to find a difference between the first binding of C14-cortisol and capacity had changed two, using a method somewhat different from (Table IV) . ing in general the pattern shown in Figure 1 .
The binding of C'4-cortisol exhibited by HSA is small but of high capacity, as evidenced by the low decreases in binding with increasing concentrations of cortisol. As can be seen (Table VI) , binding capacity was decreased in postoperative patients (see first paragraph under Results). Effects of ACTH and corticosteroids. Administration of ACTH intravenously (40 units over a period of 6 hours) to patients with cancer resulted in elevated 17-OHCS, causing a decreased C14-cortisol binding and transcortin capacity (Table VII) . The same was true when a patient with cancer was given cortisol intravenously. The small changes observed in the binding upon the addition of 1 ,g of cortisol, seen in some patients with cancer given ACTH or following surgery, in face of a fairly high percentage of C14-cortisol bound, are of interest. The administration of 9a-fluorocortisol resulted in insignificant changes in transcortin binding of C14-cortisol and transcortin capacity. One might not expect a change in the binding of C14-cortisol or in the transcortin capacity when the 17-OHCS levels decrease slightly or do not change, as occurred following the administration of 9a-fluorocortisol.
In Table VIII is shown the binding by plasma or 1 per cent HSA of various C14-steroids. In addition, plasma was dialyzed against HSA in order to cancel the effects of the plasma albumin on the binding (1) . This procedure showed that A4-androstenedione is predominantly bound to the serum albumin and that transcortin shows little affinity for the dihydro (H2E) and tetrahydro (H4E) derivatives of cortisone, aldosterone and 6a-methyl-prednisolone. In the case of C'4-aldos- 16 per cent of /3-globulin, and 28 per cent of y-globulin. The mean total protein concentration in the sera of these patients was 5.92 g per 100 ml. Paper electrophoretic analysis of the sera revealed 39 per cent albumin, 9 per cent a1-globulin, 13 per cent a2-globulin, 20 per cent /3-globulin, and 19 per cent y-globulin.
The binding of C14-cortisol by erythrocytes. A study was made of the binding of C'4-cortisol by erythrocytes in subjects given estrogens, in order to determine whether the increased binding exhibited by the plasma is also shown by the red blood cells. The binding was determined by dialyzing a 10 per cent suspension of red blood cells against saline. Even though there was an increase in the binding of C14-cortisol (control binding 0 to 10 per cent) to as high as 46 per cent, the addition of 1 jug of cortisol abolished all the binding of C14-cortisol (0 to 4 per cent).
Transcortin changes in a subject with Addison-'s disease. A subject with known Addison's disease and with no demonstrable 17-OHCS levels in his blood or urine was taken off cortisone therapy for a period of 4 days. The patient was then given stilbestrol (1 mg three times daily for 4 days) and the transcortin binding of C14-cortisol and capacity were determined. The binding of C14-cortisol by the control (before estrogen administration) plasma was 98 per cent, with a transcortin ca-pacity of 22 per cent, whereas following the administration of the estrogen the binding was 98 per cent, with a capacity of 6 per cent, indicating a definite effect of estrogen on the transcortin concentration in this patient. The 17-OHCS levels remained at zero during the stilbestrol administration.
DISCUSSION
The data of the present study extend our observations on the effect of estrogens on the plasma transcortin levels in human subjects. The results indicate that rises in transcortin binding and capacity precede the elevation of 17-OHCS in the plasma, suggesting that the increases in the corticosteroid levels observed in conditions with high transcortin levels (pregnancy, estrogen administration) may be due to the inability of the body to metabolize transcortin-bound cortisol with resultant increase in plasma corticosteroid levels. The rises in the transcortin levels induced by estrogens occurred as early as 3 days after commencement of therapy and, although observed with all known active estrogens given, they depended on the dose of the steroid administered. Thus, 2.5 mg of Premarin daily failed to induce a rise, whereas 10 mg did. On the other hand, as little as 3 mg daily of stilbestrol or 0.5 mg daily of ethinyl estradiol produced definite elevations of transcortin levels. It should be pointed out that on the basis of bioassay the following equivalents have been shown: 1.25 mg of Premarin has the activity of 600 to 800 rat units, 1 mg of stilbestrol, 1,500 rat units, and 0.1 mg of ethinyl estradiol, 1,200 rat units (9) . From the data shown it would appear that a minimum of 5,000 rat units per day must be administered in order to induce a demonstrable increase in transcortin concentration. The increased transcortin levels returned to normal concentrations within 1 to 2 weeks following cessation of effective estrogen therapy, with the 17-OHCS concentrations declining to normal levels soon after. Herrmann, Schindl and Bondy (10) have recently reported the failure of 5 mg of Premarin to significantly alter levels of plasma cortisol or their response to ACTH infusion, while it significantly lowered urinary excretion of adrenal steroids. These authors implied that the decreased catabolism of cortisol may be due to increased amounts of protein hinding of cortisol in plasma.
These observations are borne out by some of the data presented in this paper and by previous observations (1) (2) (3) . In addition, recently published data (3, 11, 12) substantiate the hypothesis advanced by us (1, 2) that the changes in cortisol metabolism seen during estrogen administration are due to changes in the plasma levels of transcortin.
The values, higher than those seen in normal subjects, observed for the transcortin binding of C14-cortisol in postmenopausal women with various stages of cancer of the breast may be due to the higher concentrations of transcortin, especially when considered in conjunction with the higher plasma 17-OHCS observed in these patients. At present it is difficult to state whether these increases are due to age, sex, or the disease of the patients. Further studies are necessary for clarification of this point. It is interesting to note that elevated levels of serum protein-bound iodine and possibly of serum thyroxine-binding protein have been observed in patients with progressive metastatic carcinoma of the breast (13) .
In pregnant women the transcortin levels and the 17-OHCS continued to be elevated 5 days postpartum but returned to normal 6 weeks postpartum.
Of the many steroids studied, only the known active estrogens were capable of inducing concomitant increases in transcortin and 17-OHCS levels. The changes in transcortin capacity induced by estrogens in an Addisonian subject without any demonstrable plasma or urinary 17-OHCS would seem to indicate that adrenocortical function is not necessary for the estrogens to cause increased concentrations of transcortin. The binding of C14-cortisol by erythrocytes in vivo was similar to that previously described (14) and was not greatly changed by the administration of estrogens, even though the slight increase in the binding observed may be due to some trapped plasma or binding of small amounts of transcortin to the red blood cells.
Testosterone propionate, 1 7a-methyl-19-nortestosterone, and 2a--methyl-dihydrotestosterone propionate were incapable of producing any significant changes in the concentrations of transcortin or 17-OHCS. In addition, testosterone was not able to prevent the changes in transcortin concentration indtuced by estrogen therapy while the patient was receiving large doses of testosterone. In a few instances slight increases were seen during therapy with very large doses of testosterone, changes which may possibly be due to conversion of the androgen to estrogens, as has been reported by others (15, 16) . The failure of steroids other than estrogens to cause a rise in the transcortin levels points to a specificity of action of these steroids. This is of note, especially in view of the finding that during the administration of large doses of testosterone, stilbestrol was able to cause an increase in the transcortin capacity.
Rises in the levels of 17-OHCS induced by ACTH, stress, and infusion of cortisol caused great decreases in transcortin binding of C14-cortisol and in transcortin capacity due to saturation of the protein with cortisol, which probably occurred at levels of 20 to 40 ,ug per 100 ml. With high plasma 17-OHCS levels, the conditions prevailing for the binding of cortisol and transcortin are best depicted in the right half of the "control" curve in Figure 1 . As transcortin becomes saturated with cortisol, the percentage of the steroid bound is greatly reduced and additional cortisol causes only small decreases in the amount of steroid bound. The small changes in the C14-cortisol bound upon the addition of 1 ug of cortisol seen in some patients with cancer given ACTH or following surgery, in face of a fairly high percentage of C'4-cortisol bound before the addition of the extra cortisol, may be due to several factors. It that the concentration of a,-globulin in the lymph was of about the same magnitude as that in the serum of the cancer patients. Since transcortin is found in the a,-globulin fraction, it is not surprising to find that the binding exhibited by the lymph fluids was not much lower than that found with plasma. Even though some of the other globulins were present in higher concentrations in the lymph than in the serum, these proteins have been shown to have little affinity for cortisol (14) . It should be pointed out, however, that the lymph in our studies was obtained from patients with advanced cancer and these findings may not be applicable to normal subjects. The possible presence of transcortin in some body fluids (synovial, pleural) and its absence in spinal fluid is indicated in the work of Daughaday and co-workers (7).
Daughaday and associates, in earlier work (7, 8) , failed to find a difference in the binding of labeled cortisol between normal plasma and that obtained from pregnant women or subjects receiving large doses of estrogens. They utilized undiluted plasma in equilibrium dialysis and in a competition or double dialysis, wherein plasma from pregnant women or subjects receiving estrogens was dialyzed in the same system with normal plasma, but definite differences were demonstrated, using their system of dialysis as well as ours, when diluted plasma was used. Again, we attributed Daughaday's failure to show a difference between normal and pregnant plasma, and plasma of estrogen-treated subjects, to the high equilibrium constant of transcortin associated with the use of a high protein concentration.
Daughaday and Mariz's conclusion, based on more recent work (5) , that there are two corticosteroid-binding globulins in the plasma of pregnant women or of subjects treated with estrogens, is open to another interpretation. They "compared the binding of cortisol by four plasmas of individuals with increased estrogenic activity directly to control plasma using (their) standard conditions (double equilibrium dialysis) of cortisol loading (0.5 ,ug per 10 ml of plasma) and also using 5.5 ug of cortisol per 10 ml of plasma." The ratio of the binding of cortisol by the plasma of test subjects to that of the control subjects increased with the increased cortisol load. Daughaday states that "in such a situation the relative binding of cortisol would be greatest at the lowest level of cortisol loading." This is not the case, however. Let us consider the two sigmoid binding curves shown in Figure 1 . At 0.5 ,Mg the binding of the two plasmas is nearly identical, but at 5.5 ug the ratio of binding is considerably larger than unity. Thus, Daughaday is observing the same phenomenon as we, although expressing it differently. Indeed, we are in complete accord on the facts, which in our opinion, point to the inability of any of the published methods to distinguish two corticosteroid-binding globulins in human plasma.
SUMMARY
The administration of adequate amounts of estrogens produces increased concentrations of transcortin within 3 to 7 days, followed by a rise in the levels of the 17-hydroxycorticosteroids (17-OHCS). These levels declined to normal within 7 to 10 days after cessation of estrogen treatment. The increased concentration of transcortin can be induced by estrogens in the absence of the adrenal gland.
Testosterone propionate, 17a-methyl-19-nortestosterone and 2a-methyl-dihydrotestosterone propionate failed to change the transcortin or 17-OHCS concentrations. The increased transcortin concentrations in pregnant women had changed little within 5 days postpartum and were normal 6 weeks after delivery.
ACTH, surgical stress, and intravenous cortisol decreased the transcortin binding of C14-cortisol and transcortin capacity.
Lymph fluids contain transcortin and 17-OHCS in slightly lower concentrations than those seen in plasma.
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